Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME	:	_ MEMBER'S FIRST	NAME:	
	view (e.g., chart notes or	lab data, to support tl	y. Attach any additional documentation ne authorization request). Information	
			☐ URGENT	
MEMBER INFORMATIO	N			
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRT	H:	
STREET ADDRESS:		,		
CITY:		STATE:	ZIP CODE:	
PATIENT INSURANCE	D NUMBER:			
☐ MALE ☐ FEMALE	HEIGHT (IN/CM):	_ WEIGHT (LB/KG)	: ALLERGIES:	
FOLLOWING LINK: PRIMPATIENT'S AUTHORIZE	ZATION FORM WITH TH METHERAPEUTICS.COM D REPRESENTATIVE (IF	IIS REQUEST WHICH MINOPP FAPPLICABLE):	H CAN BE FOUND AT THE	
AUTHORIZED REPRESE	NTATIVE'S PHONE NUI	MBER:		
PRESCRIBER INFORM	ATION			
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIAL	.TY:	EMAIL ADDRE	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER	:	
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:	
STREET ADDRESS:				
CITY:		STATE:	ZIP CODE:	
REQUESTER (if different than prescriber):		OFFICE CONT	OFFICE CONTACT PERSON:	
MEDICATION OR MEDI	CAL DISPENSING INFO	RMATION		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REF	QUANTITY:	
☐ NEW THERAPY	RENEWAL IF		HERAPY INITIATED:	
DURATION OF THERAF	Y (SPECIFIC DATES):			
Continued on next page				

© 2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 12.1.24 CAT009



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST N	AME:		
1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? YES (if yes, complete below) □ NO				
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
Growth hormone deficiencies WITHOUT organic pituatiry disease Growth hormone deficiences WITH organic pituitary disease Idiopathic Short Stature (ISS) Small for gestation age (SGA) Silver-Russell Syndrome(SRS) Turner's Syndrome Prader-Willi Syndrome Noonan Syndrome Short Stature Homeobox (SHOX) Syndrome Other diagnosis: ICD-10 Code(s): 3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION				
TO SUPPORT A PRIOR AUTHORIZ				
Is patient going to be using drug in combination with a clinical trial? ☐ Yes ☐ No FOR ALL REQUESTS: Has the patient tried Norditropin for at least 3 months and had an inadequate response or intolerance (unless requesting Nordotropin)? ☐ Yes ☐ No If patient has been on therapy with paid claims, is request for a dose increase only? ☐ Yes ☐ No				
patient nac accir en ancrapy and				
PEDIATRIAC PATIENTS <18 YEARS OF AGE: Is the provider a pediatric endocrinologist or in the case of chronic kidney disease, pediatric nephrologist? Yes No				
For GHD WITHOUT organic pituitary disease: Does the patient have growth failure caused by inadequate secretion of endogenous growth hormone in the absence of organic pituitary disease? Yes No				
Has growth hormone deficiency been confirmed by ONE of the following: □ TWO provocative test with results below 10 ng/ml (i.e. i.e., L-Dopa, insulin-induced hypoglycemia, arginine, glucagon, or clonidine) □ ONE provocative stimulation test less than 15 ng/mL AND a low insulin-like growth factor-1 (IGF-1) level for the patients age, gender, and pubertal status AND a low IGFBP (insulin-like growth factor binding protein-3) Documentation must be submitted				



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:
Is the patient's height below the third percentile for their age and gender related height? □ Yes □ No Documentation must be submitted
Does the patient have a decreased growth velocity of ≥ 2 standard deviations (SD) below the agerelated mean measured over 1 year? □ Yes □ No *Documentation must be submitted*
Does the patient have delayed skeletal maturation of ≥ 2 SD below the age/gender related mean? □ Yes □ No Documentation must be submitted In patient's ≥ 10 years of age, are the epiphyses confirmed as open? □ Yes □ No Documentation must be submitted
For GHD WITH organic pituitary disease: Does the patient have a diagnosis of GHD caused by an inadequate secretion of endogenous growth hormone in the presence of organic pituitary disease (e.g., head trauma, cranial irradiation, stroke, hypopituitarism, panhypopituitarism, known mutations, irreversible and/or post-surgery hypothalamic-pituitary lesions, embryopathic / congenital defects of the pituitary, septo-optic dysplasia)? Yes No
Is the serum IGF-1 level lower than the age-specific lower limit of normal? ☐ Yes ☐ No Documentation must be submitted
Does the MRI or CT of head show pituitary stalk agenesis, empty sella, sellar or supra-sellar mass lesion, and/or ectopic posterior pituitary "bright spot"? Yes No Documentation must be submitted
For idiopathic short stature (ISS): Does the patient have a diagnosis of non growth hormone deficient short stature? □ Yes □ No
Is the patient's height standard deviation score (SDS) of 2.25 or below the mean chronological age and sex? □ Yes □ No Documentation must be submitted
Have other causes such as genetic, metabolic, or organ system dysfunction been ruled out and documented? □ Yes □ No Documentation must be submitted
For chronic kidney disease: Has the patient received a renal transplant? □ Yes □ No
Is the patient's height below the 3rd percentile for their age and gender related height? ☐ Yes ☐ No Documentation must be submitted
Small for Gestational Age (SAG), including Silver-Russell Syndrome: Was the patient born small for gestational age (SGA), defined as birth weight and/or birth length two or more SDs below the mean for gestational age? No





Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
	growth by 2-4 years of age, defined as two or more SDs below height for age and sex? □ Yes □ No
	ally defined syndrome known to cause short stature due to cluding Down Syndrome (Trisomy 21)? ☐ Yes ☐ No
Does the patient have congenital bor ☐ Yes ☐ No Documentation must be submitted	ne dysplasia, including achondroplasia and hypochondroplasia?
For Turner's syndrome: Was the patient's diagnosis confirme Documentation must be submitted	ed by chromosome analysis? □ Yes □ No
Does the patient's height fall below the Documentation must be submitted.	he 5th percentile for chronological age and sex? □ Yes □ No
Has the patient's growth velocity, pri bone growth cessation? □ Yes □ No Documentation must be submitted.	or to age 14 years, decreased to less than 2 cm /year prior to
predicted based on the mean parenta	nild's height for age is less than or equal to 50% of that all height for females ?(mean predicted height in centimeters = 5 cm). Yes No Documentation must be submitted.
	diagnosis confirmed by genetic testing (loss of gene function h as translocation or maternal uniparental disomy)? □ Yes □
Has an assessment of underlying air Yes □ No Documentation must be submitted	way obstruction including sleep studies been completed?
Does the patient have any of the folious severe obesity □ history of upper airway obstruction □ respiratory compromise □ severe sleep apnea	
For Short Stature Homeobox (SHOX) analysis?	deficiencies: Was the diagnosis confirmed via chromosomes



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
	alone or with multiple hormone deficiencies (such as disease, hypothalamic disease, surgery, radiation therapy,
Is the patient's serum IGF-1 concentration ptient who has organic pituitary disease Documentation must be submitted	ion lower than the age-specific lower limit of normal in a e? □ Yes □ No
Does that patient have a subnormal GH arginine-GHRH (<4.1ng/mL)? □ Yes □ Documentation must be submitted	response to insulin-induced hypoglycemia (<5.1 ng/mL) or No
For Adults with childhood-onset GHD: Does the patient have childhood-onset causes? □ Yes □ No	GHD as a result of congenital, acquired, or idiopathic
height has been achieved and subnorm	month after GH therapy has been discontinued and final lal responses to at least one standard GH stimulation test ☐ Yes ☐ No
hypopituitarism, panhypopituitarism, ki	disease (e.i. head trauma, cranial irradiation, stroke, nown mutations, irreversible and/or post-surgery pathic / congenital defects of the pituitary, septo-optic
Does the patient have past OR current I reference range without GH therapy? Documentation must be submitted	IGF-1 levels that are below the age- and sex-appropriate □ Yes □ No
Has the patient had a subnormal GH res (<5.1ng/ml) or arginine-GHRH (<4.1ng/m	sponse to insulin-induced hypoglycemia hypoglycemia nl)? □ Yes □ No
ZORBTIVE only: Does the patient have or damaged bowel? □ Yes □ No	a diagnosis of short bowel syndrome as a result of resected
Does the patient have any of the followi chronic diarrhea weight loss electrolyte imbalances malnutrition dehydration malabsorption of fats, vitamins and neces	



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
Is the patient receiving specialize Yes □ No Documentation must be submitte	ed nutrional support (i.e. parenteral nutrion or enteral feedings)?
REAUTHORIZATION Pediatric patients < 18 years of a Does the patient have one of the growth hormone deficiency small for gestational age (SGA idiopathic short stature (ISS) growth failure due to Turner's Noonan Syndrome	following diagnosis: a) including Silver-Russell Syndrome
 □ Short stature homeobox (SHO) □ chronic kidney disease 	X) deficiency
Are the patient's epiphyses open	? □ Yes □ No
	age of up to 16 years of age, is the patient's growth response at owth rate) or at least 2.5 cm/yr (post-puberty growth rate)? □ Yes
	e age of up to 14 years, is the patient's growth response at least 4.5 or at least 2.5 cm/yr (post-puberty growth rate)? □ Yes □ No
For a diagnosis of Prader-Willi sy Has the patient experienced an inbenefit? Yes No	yndrome: ncrease in lean body mass, decrease in fat, or maintenance of
	ne patient experienced clinical benefit while on therap (ie increase in EF-1 and IGFBP3 levels, or increase in exercise capacity)? □ Yes □
ZORBITIVE renewal: Has the pati intravenous nutrition requiremen	ient experienced clinical benefit while on therapy (i.e. decrease in nts)? □ Yes □ No
Are there any other comments, d information the physician feels is	liagnoses, symptoms, medications tried or failed, and/or any other s important to this review?
Please note: Not all drugs/diagnos required information is received.	is are covered on all plans. This request may be denied unless all

© 2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 12.1.24 CAT009



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
	s true and accurate to the best of my knowledge. I Group or its designees may perform a routine audit and the accuracy of the information reported on this form.
Prescriber Signature or Electronic I.D. Verificati	on: Date:
CONFIDENTIALITY NOTICE: The documents accomments	ompanying this transmission contain confidential health
information that is legally privileged. If you are not t	he intended recipient, you are hereby notified that any
	reliance on the contents of these documents is strictly
prohibited. If you have received this information in	error, please notify the sender immediately (via return
FAX) and arrange for the return or destruction of th	ese documents.
FAX THIS FORM TO : 800-424-7640	

 $\textbf{MAIL REQUESTS TO:} \ \ \textbf{Prime The rapeutics Management Prior Authorization Program}$

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

